Finally, another study demonstrated that TGFβ1 levels were significantly higher in EVs isolated from the serum of patients with HER2-overexpressing BC who subsequently did not respond to neoadjuvant HER2-targeted drug treatment, compared with those who experienced complete or partial response [185]. The gene discussed is ERBB2; the disease is breast cancer.